Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sinil Pharmaceutical Co Ltd
Net Income (Common)
Sinil Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
|
Net Income (Common)
₩11.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩191.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
₩267B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩169.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
70%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
₩5.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Net Income (Common)
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Sinil Pharmaceutical Co Ltd
Glance View
Sinil Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Chungju, Chungcheongbuk-Do. The Company’s products consist of antihyperlipidemic agents, antitussives, expectorants, anti-antipyretic agents, analgesic agents, inflammatory agents, dermatological treatments, chemotherapeutic agents, antihistamines, antihypertensives and mixed vitamins, among others. The company also engages in the leasing of real estate.
See Also
What is Sinil Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
11.3B
KRW
Based on the financial report for Sep 30, 2025, Sinil Pharmaceutical Co Ltd's Net Income (Common) amounts to 11.3B KRW.
What is Sinil Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
2%
Over the last year, the Net Income (Common) growth was -25%. The average annual Net Income (Common) growth rates for Sinil Pharmaceutical Co Ltd have been 1% over the past three years , 6% over the past five years , and 2% over the past ten years .
